Clinical Leader Webinar

  1. Conducting Clinical Trials During COVID-19: Case Studies From The Perspectives Of Sponsor, CROs, Sites, And IP & CTS Distributors 5/1/2020

    We are in a challenging time that is testing our collective ability to crisis-manage on-going clinical trials. New trials are being put on hold and recruitment of patients is being suspended, given the lack of hospital staff available to manage clinical trials while healthcare systems are gearing up to handle the flood of COVID-19 patients. Here panelists provide perspectives from sponsors and clinical trial sites, and on clinical site monitoring, and clinical trial logistics.

  2. Experts From China Speak On Conducting Clinical Trials During The Pandemic 5/1/2020

    The first in our series of DIA DIRECT: COVID-19 Webinars, join us to hear from experts in China, from across various healthcare product development functions, on steps currently in place to ensure safety and efficacy of clinical trials continuing through this pandemic.

  3. COVID-19 Pandemic: Response To Regulatory Guidance 5/1/2020

    A number of non-COVID related trials are facing disruptions due to the coronavirus pandemic. Cancelled patient visits, new comorbidities, and more resource constraints have resulted in missing data, questions about recalibrated SAPs, and concerns about maintaining statistical power. Cytel co-hosted a panel to talk through some of these challenges.

  4. COVID-19: Trials, Designs And Tools For Promising Results 5/1/2020

    How can we harness the power of data science and trial design to achieve expedited clinical development for a new coronavirus vaccine? Experts from around the world weigh in on this panel.

  5. Are You Really Ready For Your End Of Phase 2 (EOP2) Meeting? 4/21/2020

    The end-of-phase 2 (EOP2) meeting with FDA is a critical milestone in your development program and likely the most important interaction you will have with the Agency. Getting the most from this meeting can help successfully launch your phase 3 program and help you begin preparing for your marketing application (NDA/BLA) submission.

  6. Patient Focused Clinical Trial Sample Collection, Management And Tracking 4/21/2020

    To address the parallel growth in advanced therapies and in clinical trial patient centric services, this webinar will discuss the challenges and strategies for a patient focused sample management plan. Topics will include the integration of home health care visits, solutions for virtual sample and product tracking, patient scheduling, and logistical solutions.

  7. Roadblocks At The On-Ramp To The Clinical Trial Participant's Journey – And How Better Data Can Remove Them 4/14/2020

    Mike Wenger, TrialScope Vice President of Patient Engagement, addresses patient challenges in accessing clinical trials. Craig Lipset, former head of innovation at Pfizer, explores new ways of approaching the industry's study recruitment dilemma.

  8. Virtual, Decentralized, Site-less Trials… What Does It All Mean 4/11/2020

    Patient-facing digital technologies are playing an increasingly important role in clinical trials, to the point where including virtual components in trials has become mainstream. Join Kathy Vandebelt, Global Head of Clinical Innovation at Oracle Health Sciences to discuss where the industry stands on terms like "virtual" or "decentralized" trials, what are the benefits and challenges, and what does the future hold for all of us involved. 

  9. Three Key Critical Considerations Before Embarking On Decentralized Trials 4/11/2020

    Trying to incorporate data collected from new patient-facing technology into a traditional protocol design and operational practices just won’t work. Join Kathy Vandebelt, Global Head of Clinical Innovation at Oracle Health Sciences to learn ways to optimize data flow in hybrid and decentralized trials to improve patient experience, data quality, and expedite the clinical trial process.

  10. Dismantling Data Silos To Improve Study Startup And Mitigate Risk 4/3/2020

    The focus on technology as a driver of performance improvement in clinical trials is intense, but despite years of valiant efforts, study execution remains far from optimal. Unfortunately, entrenched silos such as site identification, clinical development, data management, contracting and regulatory affairs have long stymied these data flow efforts because these departments often have minimal understanding of what is needed downstream.